CLASS II ONGOING Device recall · Reported 20 Aug 2025 · FDA Enforcement Report

Access Thyroglobulin assay, a simultaneous one-step recalled

Beckman Coulter is recalling Access Thyroglobulin assay, a simultaneous one-step immunoenzymatic assay, distributed nationwide in the US. The recall was initiated on 10 Jul 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesUDI-DI: 15099590227173; Lot Number: 439163
Quantity recalled453 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2322-2025
FDA event ID
97255
Recalling firm
Beckman Coulter, Chaska, MN
Classification
Class II
Status
Ongoing
Recall initiated
10 Jul 2025
FDA classified
13 Aug 2025
Reported
20 Aug 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

10 Jul 2025Recall initiated by company
13 Aug 2025Classified by FDA+34 days
20 Aug 2025Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Access Thyroglobulin reagent lot 439163 may generate erroneously high patient results. Falsely increased Access Thyroglobulin results may lead a physician to pursue unnecessary diagnostic imaging studies and/or inappropriate therapy adjustments in patients being monitored for residual or recurrent thyroid cancer.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Access Thyroglobulin assay, a simultaneous one-step immunoenzymatic assay, Catalog Number 33860

Where it was distributed

Worldwide - US Nationwide and the countries of Brazil, Canada, Georgia, Italy, Malaysia, Mexico, Philippines, Spain.

Nationwide Georgia

Questions about this recall

Why was it recalled?

Access Thyroglobulin reagent lot 439163 may generate erroneously high patient results. Falsely increased Access Thyroglobulin results may lead a physician to pursue unnecessary diagnostic imaging studies and/or inappropriate therapy adjustments in patients being monitored for residual or recurrent thyroid cancer.

Which lots are affected?

UDI-DI: 15099590227173; Lot Number: 439163

Where was it sold?

Worldwide - US Nationwide and the countries of Brazil, Canada, Georgia, Italy, Malaysia, Mexico, Philippines, Spain.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Beckman Coulter

All 334

Other Test Kits & Diagnostics recalls

All 2,658